A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation

A set of 11 genes, termed the common rejection module, predicts acute graft rejection in solid organ transplant patients and may help to identify novel drug targets in transplantation.

[1]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[2]  R. Alloway,et al.  Proteasome Inhibitor-Based Primary Therapy for Antibody-Mediated Renal Allograft Rejection , 2010, Transplantation.

[3]  L Fritsche,et al.  Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.

[4]  E. Ros,et al.  Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients. , 2010, Molecular diagnosis & therapy.

[5]  M. Hartl,et al.  Inhibition of Myc-induced cell transformation by brain acid-soluble protein 1 (BASP1) , 2009, Proceedings of the National Academy of Sciences.

[6]  H. Zou,et al.  Delay of metabolism rate of ciclosporin by simvastatin in 7 Chinese healthy men. , 1998, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[7]  P. Libby,et al.  Differential Expression of the IFN-γ-Inducible CXCR3-Binding Chemokines, IFN-Inducible Protein 10, Monokine Induced by IFN, and IFN-Inducible T Cell α Chemoattractant in Human Cardiac Allografts: Association with Cardiac Allograft Vasculopathy and Acute Rejection1 , 2002, The Journal of Immunology.

[8]  A. Cheung,et al.  A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. , 1993, Journal of the American Society of Nephrology : JASN.

[9]  A. Novick,et al.  Early increased chemokine expression and production in murine allogeneic skin grafts is mediated by natural killer cells. , 2000, Transplantation.

[10]  A. Gavazzi,et al.  Efficacy and Pharmacokinetics of Simvastatin in Heart Transplant Recipients , 1995, The Annals of pharmacotherapy.

[11]  F. Yates,et al.  Statistical methods for research workers. 5th edition , 1935 .

[12]  R. Fisher,et al.  Statistical Methods for Research Workers , 1930, Nature.

[13]  J. O'Quigley,et al.  Predictive strength of Jonckheere's test for trend: an application to genotypic scores in HIV infection , 2007, Statistics in medicine.

[14]  A. Butte,et al.  A Peripheral Blood Diagnostic Test for Acute Rejection in Renal Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  O. Grip,et al.  Atorvastatin Reduces Plasma Levels of Chemokine (CXCL10) in Patients with Crohn's Disease , 2009, PloS one.

[16]  M. Kendall.  Statistical Methods for Research Workers , 1937, Nature.

[17]  S. Liao,et al.  Lymphoid organ development: from ontogeny to neogenesis , 2006, Nature Immunology.

[18]  S. Katznelson,et al.  The effect of pravastatin on acute rejection after kidney transplantation--a pilot study. , 1996, Transplantation.

[19]  T. Paavonen,et al.  Protocol core needle biopsy and histologic Chronic Allograft Damage Index (CADI) as surrogate end point for long-term graft survival in multicenter studies. , 2003, Journal of the American Society of Nephrology : JASN.

[20]  B. Kasiske,et al.  THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2 , 2001, Transplantation.

[21]  M. Sarwal,et al.  Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. , 2003, The New England journal of medicine.

[22]  E. Shevach,et al.  Simvastatin induces Foxp3+ T regulatory cells by modulation of transforming growth factor‐β signal transduction , 2010, Immunology.

[23]  Christopher M Hickey,et al.  Expression of Many Immunologically Important Genes in Mycobacterium tuberculosis-Infected Macrophages Is Independent of Both TLR2 and TLR4 but Dependent on IFN-αβ Receptor and STAT11 , 2005, The Journal of Immunology.

[24]  Andreas Hochhaus,et al.  Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Wheeler,et al.  Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. , 2001, Kidney international.

[26]  Soldano Ferrone,et al.  Different Requirements for Signal Transducer and Activator of Transcription 1α and Interferon Regulatory Factor 1 in the Regulation of Low Molecular Mass Polypeptide 2 and Transporter Associated with Antigen Processing 1 Gene Expression* , 1998, The Journal of Biological Chemistry.

[27]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[28]  N. S. Thomas,et al.  Lck is a key target of imatinib and dasatinib in T-cell activation , 2010, Leukemia.

[29]  S. Knight,et al.  Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review , 2009, Transplantation.

[30]  B. Williams,et al.  Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  E. Ros,et al.  Biomarker Assessment of the Immunomodulator Effect of Atorvastatin in Stable Renal Transplant Recipients and Hypercholesterolemic Patients , 2010, Molecular Diagnosis & Therapy.

[32]  G. Cheng,et al.  CD40 Signaling Replaces CD4+ Lymphocytes and Its Blocking Prevents Chronic Rejection of Heart Transplants , 2000, The Journal of Immunology.

[33]  C. Lavie,et al.  Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. , 2002, Journal of the American College of Cardiology.

[34]  C. Esquivel,et al.  IFN-gamma, produced by NK cells that infiltrate liver allografts early after transplantation, links the innate and adaptive immune responses. , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  Y. Ohmori,et al.  Sulindac, a nonsteroidal anti-inflammatory drug, selectively inhibits interferon-gamma-induced expression of the chemokine CXCL9 gene in mouse macrophages. , 2006, Biochemical and biophysical research communications.

[36]  D. Fuchs,et al.  Atorvastatin suppresses interferon‐γ‐induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines , 2003, Clinical and experimental immunology.

[37]  F. Marincola,et al.  The immunologic constant of rejection. , 2008, Trends in immunology.

[38]  Purvesh Khatri,et al.  A System Biology Approach for the Steady-State Analysis of Gene Signaling Networks , 2007, CIARP.

[39]  A. Jankowska,et al.  Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. , 2008, Blood.

[40]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[41]  A. Hartmann,et al.  Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients , 2001, American Journal of Transplantation.

[42]  C. Esquivel,et al.  IFN‐γ, Produced by NK Cells that Infiltrate Liver Allografts Early After Transplantation, Links the Innate and Adaptive Immune Responses , 2005 .

[43]  R. Schmieder,et al.  Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[44]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[45]  A. Gavazzi,et al.  Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. , 1993, Transplantation proceedings.

[46]  Andrey Morgun,et al.  Molecular Profiling Improves Diagnoses of Rejection and Infection in Transplanted Organs , 2006, Circulation research.

[47]  A. Butte,et al.  Expression of complement components differs between kidney allografts from living and deceased donors. , 2009, Journal of the American Society of Nephrology : JASN.

[48]  R. Wolfe,et al.  Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. , 2000, Transplantation.

[49]  Ei-ichi Sato,et al.  Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus , 2010, Lupus.

[50]  R. Marcén,et al.  Immunosuppressive Drugs in Kidney Transplantation , 2009, Drugs.

[51]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[52]  Allen D. Delaney,et al.  Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing , 2007, Nature Methods.

[53]  J. Kaldor,et al.  Cancer incidence before and after kidney transplantation. , 2006, JAMA.

[54]  S. Quake,et al.  Universal noninvasive detection of solid organ transplant rejection , 2011, Proceedings of the National Academy of Sciences.

[55]  S. Batalov,et al.  A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Khatri,et al.  A systems biology approach for pathway level analysis. , 2007, Genome research.

[57]  Diederik F Van Wijk,et al.  Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. , 2010, Atherosclerosis.

[58]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[59]  U. Christians,et al.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.

[60]  I. Türbachova,et al.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.

[61]  Megan Sykes,et al.  Organ transplantation—how much of the promise has been realized? , 2005, Nature Medicine.

[62]  A. Butte,et al.  Progressive histological damage in renal allografts is associated with expression of innate and adaptive immunity genes. , 2011, Kidney international.

[63]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[64]  A. Butte,et al.  Drug Discovery in a Multidimensional World: Systems, Patterns, and Networks , 2010, Journal of cardiovascular translational research.

[65]  G. Mudge,et al.  Lovastatin therapy for hypercholesterolemia in cardiac transplant recipients. , 1989, The American journal of cardiology.

[66]  A. Tarakhovsky,et al.  IFN-α Priming Results in a Gain of Proinflammatory Function by IL-10: Implications for Systemic Lupus Erythematosus Pathogenesis1 , 2004, The Journal of Immunology.

[67]  David W. Johnson,et al.  HMG CoA reductase inhibitors (statins) for kidney transplant recipients. , 2009, The Cochrane database of systematic reviews.

[68]  Jeff Reeve,et al.  A molecular classifier for predicting future graft loss in late kidney transplant biopsies. , 2010, The Journal of clinical investigation.

[69]  V. Kuznetsov.  Relative avidity, specificity, and sensitivity of transcription factor-DNA binding in genome-scale experiments. , 2009, Methods in molecular biology.

[70]  I. Campbell,et al.  The Cell-Specific Induction of CXC Chemokine Ligand 9 Mediated by IFN-γ in Microglia of the Central Nervous System Is Determined by the Myeloid Transcription Factor PU.1 , 2010, The Journal of Immunology.

[71]  J. Hayball,et al.  Dasatinib suppresses in vitro natural killer cell cytotoxicity. , 2008, Blood.

[72]  T. Brand,et al.  Transforming growth factor-beta signal transduction. , 1996, Circulation research.

[73]  R. Corry,et al.  New Possibilities for Organ Allografting in the Mouse , 1973 .

[74]  P. Svensson,et al.  Evaluation of CXCL 9 and CXCL 10 as circulating biomarkers of human cardiac allograft rejection , 2015 .

[75]  David W. Johnson,et al.  HMG CoA reductase inhibitors (statins) for kidney transplant recipients. , 2009, The Cochrane database of systematic reviews.

[76]  J. D. Karkas,et al.  Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.

[77]  K. Famulski,et al.  Molecular Diagnosis of T Cell‐Mediated Rejection in Human Kidney Transplant Biopsies , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[78]  Douglas G Altman,et al.  Key Issues in Conducting a Meta-Analysis of Gene Expression Microarray Datasets , 2008, PLoS medicine.

[79]  B. Williams,et al.  Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays , 1998 .

[80]  Li Li,et al.  Differentially Expressed RNA from Public Microarray Data Identifies Serum Protein Biomarkers for Cross-Organ Transplant Rejection and Other Conditions , 2010, PLoS Comput. Biol..

[81]  R. Goldberg,et al.  Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. , 1996, Transplantation.

[82]  Daniel Hägg,et al.  Evaluation of CXCL9 and CXCL10 as circulating biomarkers of human cardiac allograft rejection , 2006, BMC cardiovascular disorders.

[83]  F. Marincola,et al.  Helper B Cells Promote Cytotoxic T Cell Survival and Proliferation Independently of Antigen Presentation through CD27/CD70 Interactions1 , 2008, The Journal of Immunology.